Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Liabilities: 2023-2025

Historic Total Liabilities for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $10.4 million.

  • Contineum Therapeutics' Total Liabilities rose 78.73% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 78.73%. This contributed to the annual value of $14.8 million for FY2024, which is 159.22% up from last year.
  • Per Contineum Therapeutics' latest filing, its Total Liabilities stood at $10.4 million for Q3 2025, which was down 9.75% from $11.5 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Total Liabilities peaked at $14.8 million during Q4 2024, and registered a low of $3.9 million during Q2 2024.
  • Moreover, its 3-year median value for Total Liabilities was $8.5 million (2024), whereas its average is $9.0 million.
  • Data for Contineum Therapeutics' Total Liabilities shows a peak YoY soared of 198.49% (in 2025) over the last 5 years.
  • Over the past 3 years, Contineum Therapeutics' Total Liabilities (Quarterly) stood at $5.7 million in 2023, then skyrocketed by 159.22% to $14.8 million in 2024, then skyrocketed by 78.73% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $11.5 million for Q2 2025, and $13.5 million during Q1 2025.